Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AbbVie Gains Lung Cancer ADC, Solid Tumor Platform With Stemcentrx Buyout

Executive Summary

As part of its strategy to offset the coming Humira patent cliff, AbbVie Inc. is looking to oncology as a "significant pillar of growth" going forward, a gambit CEO Richard Gonzalez says will benefit greatly from both the pipeline candidates and the solid tumor R&D engine his company will obtain in the $5.8bn purchase of Stemcentrx announced April 28.


Related Content

AbbVie's Rova-T Disappoints As Second-Line SCLC Trial Halted
Stock Scan March 2018: Trading Down, Pairing Up
Weak Rova-T Data May Imperil AbbVie's Larger Cancer Ambitions
New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
Immuno-Oncology 2.0 Roundtable: Emerging Players Eye Crowded Field
JnJ Not Sweating Remicade Biosimilar Approval
Venclexta Win Broadens AbbVie/Genentech CLL Positions
Humira Competition Dominates AbbVie Earnings
Merck Hep C Drug Zepatier OK'd


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts